Suchergebnisse - "Pinato, David J"

PubPharm (23)

1

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

enthalten in: Journal of hepatology | 2024

von Celsa, C. | Cabibbo, G. | Fulgenzi, C. | +69

2

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

enthalten in: JHEP reports : innovation in hepatology | 2024

von Balcar, L. | Scheiner, B. | Fulgenzi, C. | +45

3

Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram

enthalten in: Frontiers in immunology | 2024

von Losurdo, A. | Dipasquale, A. | Giordano, L. | +11

4

PETAL protocol : a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma

enthalten in: Future oncology (London, England) | 2023

von Fessas, P. | Scheiner, B. | D'Alessio, A. | +8

5

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy : A Sub-Analysis of the Spinnaker Study

enthalten in: International journal of molecular sciences | 2023

von Anpalakhan, S. | Huddar, P. | Behrouzi, R. | +14

6

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy : a Spinnaker study sub-analysis

enthalten in: Frontiers in oncology | 2023

von Anpalakhan, S. | Huddar, P. | Behrouzi, R. | +16

7

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

enthalten in: Cancers | 2022

von Wu, Y. | Fulgenzi, C. | D'Alessio, A. | +32

8

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Vithayathil, M. | D'Alessio, A. | Fulgenzi, C. | +32

CommentIn: Liver Int. 2022 Nov;42(11):2352-2353. - PMID 36162086

9

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

enthalten in: BJU international | 2022

von Makrakis, D. | Talukder, R. | Diamantopoulos, L. | +44

10

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy

enthalten in: Thoracic cancer | 2022

von Banna, G. | Tiseo, M. | Cortinovis, D. | +31